THE FINANCIAL — Nestlé announced today the successful completion of its acquisition of Aimmune Therapeutics, Inc. (Nasdaq: AIMT). Joining Nestlé Health Science (NHSc) as a stand-alone business unit called Aimmune Therapeutics, a Nestlé Health Science company, it will manage NHSc‘s global pharmaceutical business. “Nestlé Health Science’s acquisition of Aimmune Therapeutics marks an important milestone in our constant pursuit of innovative, science-based nutritional solutions to support healthier lives,” said Greg Behar, CEO of NHSc. “Aimmune’s PALFORZIA®, the first medication approved for treating peanut allergy, is a game-changer and it’s only the beginning. Aimmune’s pharmaceutical expertise and infrastructure will complement our existing research and development to…
Read More »
THE FINANCIAL — Nestlé announced today the successful completion of its acquisition of Aimmune Therapeutics, Inc. (Nasdaq: AIMT). Joining Nestlé Health Science (NHSc) as a stand-alone business unit called Aimmune Therapeutics, a Nestlé Health Science company, it will manage NHSc‘s global pharmaceutical business. “Nestlé Health Science’s acquisition of Aimmune Therapeutics marks an important milestone in our…
You might be interested in
The FINANCIAL — Over the weekend of the 6th through 7th of August 2022, US senators voted through the night…
High performing managers set harsher targets for their employees, according to new research by Vienna University of Economics and Business.…
The international theater festival named after Nodar Dumbadze was festively completed in Guria. The festival hosted guests in the Ozurgeti…